Edwards Lifesciences stock wavered Wednesday, though the heart-valve replacement maker issued a bullish outlook for 2026.

Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance ...

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

Edwards Lifesciences (NYSE:EW) reported fourth-quarter and full-year 2025 results that management characterized as strong, ...

Several medical societies supported extending Medicare coverage for TAVR to patients with asymptomatic aortic stenosis, but some physicians and rival Medtronic said more data is needed.

Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal ...

Investors reacted positively to Edwards’ 2026 guidance with shares up 1.25% in after-hours trading following the announcement.

SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) announced today that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...